Results 21 to 30 of about 5,890 (202)

Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice

Journal of Venomous Animals and Toxins including Tropical Diseases, 2019
Background: Cutaneous leishmaniasis (CL) is a parasitic disease caused by the protozoan Leishmania spp. Pentavalent antimonial agents have been used as an effective therapy, despite their side effects and resistant cases.
Samanta Etel Treiger Borborema, João Alberto Osso Junior, Heitor Franco de Andrade Junior, Nanci do Nascimento   +3 more
doaj   +2 more sources

Antimony Excretion in a Patient with Renal Impairment During Meglumine Antimoniate Therapy

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
Meglumine antimoniate was administered to a patient with visceral leishmaniasis with normal renal function. Soon after the first intramuscular administration of meglumine antimoniate 20 mg/kg, equivalent to 510 mg antimony (Sb), the patient developed septic shock with oliguria. Creatinine clearance decreased to 23 ml/minute. Treatment was discontinued,
P, Hantson, S, Luyasu, V, Haufroid, M, Lambert   +3 more
openaire   +3 more sources

Pharmacokinetics of Antimony in Children Treated for Leishmaniasis with Meglumine Antimoniate [PDF]

The Journal of Infectious Diseases, 2007
In some settings, the response to pentavalent antimonial therapy for leishmaniasis may be lower in children than in adults. We hypothesized that there are age-dependent pharmacokinetic differences of potential clinical relevance.We compared the pharmacokinetics of antimony (Sb) in adults and 2 groups of children 3-6 years old who had cutaneous ...
Cruz, Adriana Taveira da UNIFESP, Rainey, Petrie M., Herwaldt, Barbara L., Stagni, Grazia, Palacios, Ricardo, Trujillo, Rodolfo UNIFESP, Saravia, Nancy G.   +6 more
openaire   +3 more sources

Efficacy of Spironolactone Treatment in Murine Models of Cutaneous and Visceral Leishmaniasis

Frontiers in Pharmacology, 2021
Translational studies involving the reuse and association of drugs are approaches that can result in higher success rates in the discovery and development of drugs for serious public health problems, including leishmaniasis.
Valter Viana Andrade-Neto, Juliana da Silva Pacheco, Juliana da Silva Pacheco, Job Domingos Inácio, Elmo Eduardo Almeida-Amaral, Eduardo Caio Torres-Santos, Edezio Ferreira Cunha-Junior, Edezio Ferreira Cunha-Junior   +7 more
doaj   +1 more source

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis. [PDF]

Front Pharmacol, 2019
Le contrôle de la leishmaniose cutanée (CL) dans les Amériques dépend de la chimiothérapie avec des antimoniaux pentavalents parentéraux. Des taux élevés d'échec thérapeutique incitent à rechercher des marqueurs prédictifs et pronostiques de la réactivité thérapeutique.
Vargas DA, Prieto MD, Martínez-Valencia AJ, Cossio A, Burgess KEV, Burchmore RJS, Gómez MA.   +6 more
europepmc   +7 more sources

Glutathione-Induced Conversion of Pentavalent Antimony to Trivalent Antimony in Meglumine Antimoniate [PDF]

Antimicrobial Agents and Chemotherapy, 2001
ABSTRACT The standard treatment of human leishmaniases involves the use of pentavalent antimony [Sb(V)] compounds, including meglumine antimoniate. The mode of action of these compounds has not been fully elucidated. The possibility that Sb(III) is involved has been suggested; however, the biomolecule that may induce the ...
F, Frézard, C, Demicheli, C S, Ferreira, M A, Costa   +3 more
openaire   +2 more sources

Indications for treatment with intralesional meglumine antimoniate.

, 2021
Indications for treatment with intralesional meglumine antimoniate.
Luciana de Freitas Campos Miranda (7871216), Leonardo Pereira Quintella (10017666), Raquel de Vasconcellos Carvalhaes de Oliveira (3203967), Claudia Maria Valete-Rosalino (7871234), Armando de Oliveira Schubach (603149), Aline Fagundes (4054378), Marcelo Rosandiski Lyra (10017675), Cintia Xavier de Mello (10017657), Ana Cristina da Costa Martins (11473515), Maria Inês Fernandes Pimentel (7871222), Érica de Camargo Ferreira e Vasconcellos (4054375), Liliane de Fátima Antonio Oliveira (11473509), Eliame Mouta-Confort (4054396), Carla Oliveira-Ribeiro (11473506), Fatima Conceição-Silva (11473512)   +14 more
core   +1 more source

Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis

Journal of the College of Physicians and Surgeons Pakistan, 2023
To compare the efficacy and safety of meglumine antimoniate and miltefosine in the treatment of cutaneous leishmaniasis in Pakistan.Randomised-controlled trial. Place and Duration of the Study: Department of Dermatology, Combined Military Hospital, Lahore and Peshawar, from January to December 2021.Smear positive and/or skin biopsy-confirmed cases of ...
Atiya, Rahman, Moizza, Tahir, Tehseen, Naveed, Mohammad, Abdullah, Nida, Qayyum, Danish Hafeez, Malik, Bushra, Amin   +6 more
openaire   +2 more sources

In Vitro Reduced Susceptibility to Pentavalent Antimonials of a Leishmania infantum Isolate from a Human Cutaneous Leishmaniasis Case in Central Italy

Microorganisms, 2021
Cutaneous leishmaniasis (CL) caused by Leishmania (Leishmania) infantum is endemic in the Mediterranean basin. Here we report an autochthonous case of CL in a patient living in central Italy with an unsatisfactory response to treatment with intralesional
Aurora Diotallevi, Gloria Buffi, Giovanni Corbelli, Marcello Ceccarelli, Margherita Ortalli, Stefania Varani, Mauro Magnani, Luca Galluzzi   +7 more
doaj   +1 more source

Cost-effectiveness study of therapeutic approaches for mucosal leishmaniasis [PDF]

Cadernos de Saúde Pública
: This study aimed to estimate the cost-effectiveness of four therapeutic approaches available for mucosal leishmaniasis in Brazil: miltefosine, meglumine antimoniate, combined with and without pentoxifylline, and liposomal amphotericin B.
Janaína de Pina Carvalho, Gláucia Cota, Mariana Lourenço Freire, Endi Lanza Galvão, Sarah Nascimento Silva, Tália Santana Machado de Assis   +5 more
doaj   +1 more source